Aerie Pharmaceuticals Competitors and Similar CompaniesClear all

Aerie Pharmaceuticals's competitors and similar companies include Sorrento Therapeutics, Catalyst Pharmaceuticals, scPharmaceuticals and Olainfarm.
Aerie Pharmaceuticals
Aerie Pharmaceuticals
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.
Sorrento Therapeutics
Sorrento Therapeutics
Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.
scPharmaceuticals
scPharmaceuticals
scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery.
Olainfarm
Olainfarm
Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia.
Founding Date
Founding Date
2005
Founding Date
2006
Founding Date
2002
Founding Date
2014
Founding Date
1972
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Irvine, US HQ
Dublin, IE
千代田区, JP
Henley On Thames, GB
Bedminster, US
Durham, US
Locations
San Diego, US HQ
San Diego, US
Locations
Coral Gables, US HQ
Locations
Burlington, US HQ
Locations
Olaine, LV HQ
Employees
Employees
3808% increase
Employees
31019% decrease
Employees
7649% increase
Employees
96256% increase
Employees
2,191
Valuation ($)
Valuation ($)
722.2 m
Valuation ($)
1.5 m
Valuation ($)
2.6 b
Valuation ($)
221.6 m
Valuation ($)
150.2 m

Financial

Revenue (est.)
Revenue (est.)
$194.1m (FY, 2021)
Revenue (est.)
$62.8m (FY, 2022)
Revenue (est.)
$491.7m (FY, 2024)
Revenue (est.)
$36.3m (FY, 2024)
Revenue (est.)
€122.2m (FY, 2020)
Cost of goods
Cost of goods
$26.8m (FY, 2021)
Cost of goods
N/A
Cost of goods
$68.8m (FY, 2024)
Cost of goods
$11.4m (FY, 2024)
Cost of goods
€44.5m (FY, 2020)
Gross profit
Gross profit
N/A
Gross profit
N/A
Gross profit
$422.9m (FY, 2024)
Gross profit
$25m (FY, 2024)
Gross profit
€80.1m (FY, 2020)
Net income
Net income
($74.8m) (FY, 2021)
Net income
($577.8m) (FY, 2022)
Net income
$163.9m (FY, 2024)
Net income
($85.1m) (FY, 2024)
Net income
€9.5m (FY, 2020)

Funding

Total funding raised
Total funding raised
$ 388.6m
Total funding raised
$ 42.6m
Total funding raised
N/A
Total funding raised
$ 62.5m
Total funding raised
N/A
For sources of this data, please see the company profile

View Company Profiles

Sorrento Therapeutics
HQ
San Diego, US
Employees
310↓ 19% decrease

Sorrento Therapeutics is focused on the development of proprietary drug therapeutics for addressing unmet medical needs.

View company
Catalyst Pharmaceuticals
HQ
Coral Gables, US
Employees
76↑ 49% increase

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.

View company
scPharmaceuticals
HQ
Burlington, US
Employees
96

scPharmaceuticals, a biopharmaceutical company, develops a portfolio of transformative pharmaceutical products for subcutaneous delivery.

View company
Olainfarm
HQ
Olaine, LV
Employees
2,191

Olainfarm manufactures and distributes chemical and pharmaceutical products primarily in Latvia.

View company